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administrations) was individualised according to the clinical status of the patient and
dosimetry data from either a tracer study or previous administrations. Three-
dimensional tumour dosimetry was also performed for 8 patients.
Results: Mean administered activity: 11089 +/- 7222 MBq, mean whole-body dose for a
single administration: 1.79 +/- 0.57 Gy. Tumour absorbed doses varied substantially
(3.70 ± 3.37 mGy/MBq). CTCAE grade 3/4 neutropenia was documented following
82% treatments, grade 3/4 thrombocytopenia following 71% treatments. Further acute
toxicity was seen in 49% of patients. All acute toxicities resolved with appropriate
therapy. 58% patients had complete or partial response following therapy and 29%
patients had stable disease.
Conclusion: Excellent response rates and acceptable toxicity were seen following
individualised 131I-mIBG therapy. Due to the considerable variability in patient age and
status, the absorbed doses delivered to tumours and to the whole-body per MBq
administered, a highly personalised approach is required, combining patient-specific
dosimetry and clinical judgement. This approach is enabled by the high activities that
can be tolerated by patients, particularly with stem cell support.
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 Abstract  
 
 
Objective: 131I-mIBG therapy is an established treatment modality for 
relapsed/refractory neuroblastoma, most frequently administered according to fixed or 
weight-based criteria. We evaluate response and toxicity following a dosimetry based, 
individualised approach.  
Materials and methods: A review of 44 treatments in 25 patients treated with 131I-
mIBG therapy. Patients received 131I-mIBG therapy following relapse (n=9), in 
refractory disease (n=12), or with surgically unresectable disease despite conventional 
treatment (n=4). Treatment schedule (including administered activity  and number of 
administrations of mIBG) was individualised according to the clinical status of the 
patient and dosimetry data from either a tracer study or previous administrations. 
Three-dimensional tumour dosimetry was also performed for 8 patients. 
Results: Mean administered activity: 11089 +/- 7222 MBq, mean whole-body dose 
for a single administration: 1.79 +/- 0.57 Gy. Tumour absorbed doses varied 
substantially (3.70 ± 3.37 mGy/MBq). CTCAE grade 3/4 neutropenia was 
documented following 82% treatments, grade 3/4 thrombocytopenia following 71% 
treatments. Further acute toxicity was seen in 49% of patients. All acute toxicities 
resolved with appropriate therapy. 58% patients had complete or partial response 
following therapy and 29% patients had stable disease. 
Conclusion: Excellent response rates and acceptable toxicity were seen following 
individualised 131I-mIBG therapy. Due to the considerable variability in patient age 
and status, the absorbed doses delivered to tumours and to the whole-body per MBq 
administered, a highly personalised approach is required, combining patient-specific 
dosimetry and clinical judgement.  
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Introduction 
 Neuroblastoma is an embryonal tumour of childhood arising from the neural crest. 
The majority of patients have high-risk disease at presentation, which is associated 
with a poor outcome despite intensive multimodal therapy. Targeted Molecular 
Radiotherapy (TMRT) with 131Iodine labelled meta-iodobenzylguanidine (131I-mIBG) 
has been used for patients with relapsed and refractory disease and as an induction 
and consolidation therapy for over 20 years [1-7], although reported treatment 
schedules vary widely and are hard to standardise due to the wide range of 
presentations, including disease status, patient age and treatment history. An 
individualised approach to treatment is therefore required to maximise therapeutic 
potential. 
 Although 131I-mIBG is usually administered either as a fixed activity [8] or 
according to patient weight [9-11], an alternative approach is to modify the 
administration according to a prescribed whole-body absorbed dose (WBD), which 
offers the possibility to deliver large activities and to maximise the absorbed doses 
delivered to disease sites without unnecessary toxicity [12, 13]. Administrations can 
be further increased with stem cell support. It has previously been demonstrated that 
the prescribed WBD can be delivered accurately and closely correlates with 
haematological toxicity, thereby acting as a surrogate biomarker for red marrow 
absorbed dose [14]. 
 The aim of this study was to evaluate the response, toxicity and long-term outcome 
of 131I-mIBG therapy in the treatment of refractory and relapsed neuroblastoma, based 
on an individualised approach: Administrations were tailored to patients according to 
their bio-kinetics in addition to their clinical status at the time of 131I-mIBG therapy 
including: age, stage, previous therapies, site(s) of disease, and response to previous 
therapies. 
 
Materials and Methods 
 
Ethical Considerations 
 131I-mIBG therapy is considered a standard treatment option in patients with 
relapsed and refractory neuroblastoma. For all patients who received 131I-mIBG 
therapy, clinical details were scrutinised in an institutional multidisciplinary meeting, 
and consensus regarding treatment was reached. Informed written consent was 
obtained before therapy for all patients. Institutional review board approval was 
obtained for the retrospective collection of clinical data throughout follow up at our 
institution. 
 
Patients 
 A review was conducted of 44 131I-mIBG treatments given between 1994 and 2013 
in 25 patients with a histologically proven diagnosis of neuroblastoma. Patients were 
considered eligible for 131I-mIBG therapy if there was greater tumour uptake than in 
normal liver, following relapse (n=9), in refractory disease (n=12), or with surgically 
unresectable disease despite conventional treatment (n=4).  
 A median of 2 different chemotherapy regimens was given prior to 131I-mIBG 
therapy (range 1-5). In addition, 8/25 patients had previously received high dose 
chemotherapy with autologous stem cell rescue and 6 patients had previously received 
external beam radiotherapy. Patient characteristics are shown in Table 1. 
 131I-mIBG therapy 
 Patients were treated in a room specially designed for radioisotope therapy within 
the children’s ward. 131I-mIBG was given intravenously over 2 hours with hydration. 
Thyroid protection was provided with potassium iodide. Blood pressure and heart rate 
were monitored during the procedure and for 24 hours after treatment. For the first 
treatment, 15 patients received a tracer study from which the activity required to 
deliver a WBD of 2 Gy was calculated. The initial administered activity for the 
remaining 10 patients was calculated from a simple weight-based formula of 444 
MBq/kg followed by an adjustment to the administered activity according to a 
measured WBD for subsequent therapies. 
 The methodology for whole-body dosimetry has been described previously [14, 
15]. Briefly, lead shielded ceiling mounted counters (a NaI detector for 123I tracer 
studies and a compensated Geiger counter for 131I-mIBG therapies) were used to 
acquire whole body counts. The first measurement was acquired immediately after 
administration and before the first bladder void to obtain the reading corresponding to 
100% activity. Subsequent readings were taken consistently after the child’s natural 
void and were not performed overnight, unless the child woke naturally. Between 40 
and 60 readings were acquired to define multi-exponential effective decay phases. 
The cumulated activity was determined from the integral of the curve, extrapolated to 
infinity. The absorbed dose was calculated according to the MIRD schema [16], using 
an S-factor modified according to patient weight. 
 
Tumour dosimetry 
 Image data were obtained to calculate tumour-absorbed doses for 8 of the 25 
patients. Between 3 and 8 SPECT acquisitions were made on consecutive days 
following the treatment, depending on patient availability and remaining activity. 
Scans were acquired on a Philips Forte (Philips Medical Systems, Milpitas, CA) or a 
GE Millennium VG gamma camera (GE Healthcare, Waukesha, WI) using high-
energy general-purpose collimators and a 128 x 128 matrix were used, with the same 
camera used for all scans for any given patient. Image processing and reconstruction 
were performed with Triple Energy Window scatter correction (20% photopeak 
energy window centred on 364 keV, with a 6% window of the peak on either side), a 
uniform attenuation correction (Chang) and deadtime corrections determined 
experimentally for each camera [17]. Reconstructed scans for each patient were 
sequentially co-registered to allow 3D voxelised dosimetry to be performed with an 
in-house dosimetry software package (Qrius) [18]. This software is based on patient-
specific convolution dosimetry calculations at the voxel level, with 131I absorbed dose 
voxel kernels generated using the general purpose Monte Carlo code EGSnrc/EGS++ 
[19].The radiation spectra of 131I used to calculate dose voxel kernels was taken from 
the MIRD decay Scheme [20].The image-based 3D dosimetry application provides an 
absorbed dose map of consecutive therapies from which dose volume histograms 
were derived.  
 
 
Toxicity 
 Acute toxicity was defined as any consequence arising from the point of 
administration until neutrophil count recovery to 1. Acute and long-term treatment 
toxicity was assessed in all patients by electronic record and case note review. In 
patients where data were available (those whose blood counts were monitored at our 
institution post 131I-mIBG therapy) haematological toxicity was graded according to 
Common Terminology for Adverse Events (CTCAE) criteria version 4.0. 
 
Response assessment, follow up and survival analysis 
 Following 131I-mIBG therapy, response was assessed by a combination of 
diagnostic 131I-mIBG scanning and cross-sectional imaging (CT or MRI) which was 
chosen in accordance with the base line imaging modality to enable a direct 
comparison. Imaging was reviewed by at least 2 radiologists and consensus response 
was classified according to the International Neuroblastoma Risk Classification 
(INRC) definition of response. 
 Overall survival (OS) analysis was performed using the Kaplan Meier method and 
one year OS and median OS calculated. Any further therapy given to consolidate 131I-
mIBG response was also recorded. 
 
Statistical Analysis 
 Statistical analysis was performed with GraphPad Prism software (version 6.00, La 
Jolla, CA, USA) using a two-tailed t test for paired data (Wilcoxon matched-pairs 
signed rank test in the case for non-parametric data). A double-sided P value of less 
than 0.05 was considered significant. 
 
Results 
 
Whole body Dosimetry 
 The administered 131I-mIBG activity and whole body absorbed dose for each 
patient is shown in Table 2. The mean administered activity was 11089 MBq (range 
3539 – 32871 MBq, SD 7222). The mean 131I-mIBG WBD was 1.79 Gy (range 0.93-
3.51, SD 0.57). The median interval between treatments was 67 days (range 15-1134 
days, IQR 45-94).  The use of tracer and weight-based methods to prescribe a 
therapeutic administration enabled substantially higher activities to be delivered than 
is standardly the case with fixed activity administrations although as previously 
reported, both methods slightly overestimated the absorbed whole body dose 
delivered during therapy [15]. There was no difference between WB dose predicted 
from a previous therapy and the delivered WBD (P=0.28), thus indicating the 
predictive power of consecutive therapies. 
 
Tumour dosimetry 
 A representation (studies no. 2, 20 and 25) of patient tumour dosimetry utilizing 
the 3D dosimetry tool is given in Figure 1. The generated 3D absorbed dose maps 
with isodose curves enable dose volume histograms (DVH) to be produced to 
evaluate the spatial heterogeneity of absorbed dose following therapy.  
 Tumour absorbed doses were calculated for 8 patients and are summarised in 
Figure 2. The mean tumour absorbed dose delivered was 43.7± 27.5 Gy, while mean 
liver and kidney doses were 5.7 ± 1.4 and 2.5 ± 0.4 Gy respectively. Allowing for the 
uncertainty in the dosimetry the absorbed doses delivered were consistent. Absorbed 
dose ratios between consecutive therapies are summarised in Table 3.  
 
Toxicity 
 CTCAE grade 3/4 neutropenia was seen following 18/22 (82%) treatments and 
grade 3/4 thrombocytopenia following 19/24 (71%) treatments. Autologous stem cell 
transplant was given following 131I-mIBG therapy in 14/24 patients. In addition to the 
haematological toxicity, further acute toxicity was documented following 21/43 
(49%) treatments. With the exception of 4 treatments, all acute toxicity involved 
either culture negative fever or documented infection. Of the 4 patients who had non-
fever/infection related complications: 2 patients experienced parotitis, 1 patient had a 
hypertensive episode and 1 patient complained of back pain. All acute toxicities 
resolved with appropriate therapy. With regards to potentially vulnerable target 
organs such as the liver, kidneys and thyroid gland, one patient with a transient fever 
had an associated transaminitis, although there was no long-term target organ toxicity 
seen in any patient. Only one patient, who did not receive stem cell rescue, 
experienced prolonged thrombocytopenia. 
 
 
Response 
 Data were available on response in 24/25 patients (Table 4). Two patients achieved 
CR after 131I-mIBG therapy. The first patient remained in CR for 11 months before 
relapse (at time of writing is alive with disease 16 months post 131I-mIBG therapy).  
The second patient relapsed 6 months after 131I-mIBG therapy and subsequently died 
of disease. 
 Two patients with PR following 131I-mIBG therapy subsequently achieved CR 
after further consolidation therapy. One patient who had previously received multiple 
lines of chemotherapy, surgery and high dose therapy for metastatic neuroblastoma 
had a localised recurrence that was surgically unresectable. She received 5 cycles of 
131I-mIBG therapy with a continued PR after each cycle, then further treatment with 
surgical resection, radiotherapy and cis-retinoic acid treatment. She remains alive and 
disease free after 6 years of follow up. The second patient had a surgically 
unresectable localised disease despite multiple previous lines of chemotherapy. PR 
following 131I-mIBG therapy enabled surgical resection. This was consolidated with 
radiotherapy and she remains alive and disease free 12 years from diagnosis. The 
median overall survival was 18.6 months (95% CI 10.4-26.9) with one year overall 
survival of 65% (95% CI 48-88%). The median follow up was 44 months (Fig. 3). Six 
patients were alive with disease at last follow up (median follow up from 131I-mIBG 
therapy 12 months, range 4-32 months), while 16 patients are known to have died 
from disease. The median time from the last 131I-mIBG therapy to death was 12 
months (range 2-82 months).   
 
 
Discussion 
 Cumulative evidence from institutional reports and some early phase trials has 
established 131I-mIBG therapy as a standard treatment option in patients with relapsed 
and refractory neuroblastoma [2, 8, 9, 13]. There has also been limited use of 131I-
mIBG as part of first line treatment [4, 7]. However, to date there are currently no 
published randomised controlled trials of 131I-mIBG therapy for neuroblastoma at any 
stage of treatment [21]. In order to maximise the therapeutic potential of 131I-mIBG 
therapy, well designed clinical trials incorporating dosimetry are needed. A whole 
body absorbed dose approach for 131I-mIBG therapy as followed here enables safe 
delivery of substantially higher activities than are standardly given with fixed 
administrations and can be used to deliver reproducible therapy results on a patient-
specific basis [14, 22]. 
Patients with stage III or stage IV neuroblastoma present with tumours of varying 
sizes and uptake distributions. There is a wide inter-patient variation in the absorbed 
doses delivered to tumours, although these are consistent between consecutive 
therapies. The heterogeneity of the absorbed dose distribution will affect the outcome 
of subsequent therapies and may help to explain the variation in responses. In light of 
this, a 3D dosimetry approach with DVHs could help with the development of more 
effective treatment protocols. The data in this study were acquired without the benefit 
of SPECT/CT imaging for attenuation correction. Current hybrid scanners will enable 
improved image quantification for more accurate dosimetry. 
 It is difficult to make direct comparisons of trials of 131I-mIBG therapy in 
neuroblastoma as the study groups are very heterogeneous and treatment protocols, 
including administration and concomitant therapy, are highly variable. 131I-mIBG 
therapy is often administered with a fixed or weight-based activity and with these 
techniques, response rates (PR and CR) vary between 30 and 56% [1, 8, 23]. Within 
this context our response rate of 58%, with 88% of patients having stable disease or 
better following 131I-mIBG therapy is of note. Our data also support a previous study 
showing that a dosimetry based approach to augment mIBG intensity may improve 
response rates [13]. It is also noteworthy that in our series in two cases a CR was 
obtained following either surgery or radiotherapy consolidation after mIBG therapy 
and that in several cases the duration of response was long. 
Administrations based on fixed activities must inevitably be limited according to the 
most vulnerable of patients.  This can lead to under-treatment of the majority. As 
found in this study an individualised approach, based on patient pharmacokinetics, 
will often result in the administration of higher activities. The capacity to include 
stem cell support and concomitant chemotherapy necessitates a multidisciplinary 
approach and specialised care as detailed in the EANM guidelines [24]. 
 As this report is a retrospective collation of data from patients who received 
individualised 131I-mIBG therapy schedules based on their clinical features and 
dosimetry there are a number of inherent limitations. Our patient group was 
heterogeneous in many ways; they had different disease stages and tumour burdens, 
had received various different previous chemotherapy regimens, and 131I-mIBG 
therapy was used under several different clinical scenarios. However, although the 
heterogeneity in our patient group makes drawing direct comparisons with other 
series difficult, this is a true reflection of the diverse nature of the clinical situations 
where 131I-mIBG therapy is applied in standard clinical practice. 
Neuroblastoma has an extremely variable clinical picture with regards to site(s) of 
presentation, tumour biology and disease aggressiveness. In infants with metastatic 
disease their disease may spontaneously regress. However, metastatic disease in older 
patients is associated with rapid progression and a poor prognosis. Other patients may 
have surgically unresectable localised disease compressing vital structures but with 
differentiated histology and little propensity to metastasise. In such a heterogeneous 
group of patients an adaptive approach that incorporates adjustment of dose and 
schedule, according to clinical judgement, based on a patient’s individual needs and 
dosimetry may maximise the potential benefit to the patient.  
 A limitation of our study is that there is a significant amount of missing data 
specifically on haematological toxicity. This is because patients are referred for 131I-
mIBG therapy from a wide geographical area and blood counts following therapy are 
monitored at the patients’ local institution. This is a common situation with this 
relatively rare and highly specialised treatment and indicates the need for a Europe-
wide initiative to ensure data collection. Nevertheless our reported haematological 
toxicity is as expected following 131I-mIBG therapy and previous work from our 
institution has demonstrated the clear correlation between the absorbed whole body 
dose and haematological toxicity [14]. Data on non-haematological toxicity is more 
complete due to a ‘shared care’ system whereby the treating centre is notified by local 
hospitals of any admission or problems requiring intervention. Further non-
haematological toxicities seen in our patients were all resolved with appropriate 
treatment and no long-term effects were seen. 
 In summary, excellent response rates have been seen in our institution following 
individualised 131I-mIBG therapy whilst keeping toxicity within acceptable limits. 
Our data supports the use of patient-specific dosimetry in future clinical trials to 
maximise the efficacy of 131I-mIBG  therapy. 
 
 
Conclusion 
 131I-mIBG therapy is a safe and effective treatment for relapsed or refractory 
neuroblastoma. A highly personalised approach, combining clinical judgment with 
patient-specific dosimetry can be used to safely maximise therapeutic efficacy. 
Further multi-centre clinical trials are essential to optimise the treatment and to 
determine its place within the patient pathway. 
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Fig. 3. Kaplan-Meier plot of overall survival (OS). 
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Table 1 Patient Characteristics 
Characteristic Value 
Sex (%)  
Male 15/25 (60%) 
Female 10/25 (40%) 
Median age at diagnosis (range) 53 months (5-229) 
Median age at 1st 131I-mIBG   therapy (range) 72 months (17-241) 
Stage at diagnosis* (%)  
2 3/25 (12%) 
3 4/25 (16%) 
4 18/25 (72%) 
*Stage according to International Neuroblastoma Staging System 
 
Table 1
Table 2  Administered activities (AA) and whole body absorbed dose (WBD) 
Study no. 
AA 
(MBq) 
Weight (MBq/kg) 
WBD 
(Gy) 
1a 
1b 
6611 
6605 
398 
398 
1.70 
1.61 
2a 
2b 
2c 
2d 
2e 
10524 
15673 
19811 
19723 
13988 
357.9 
517.2 
649.5 
644.5 
466.3 
1.00 
1.37 
1.62 
2.2 
1.13 
3a 
3b 
29378 
32710 
391.2 
352.5 
1.78 
1.12 
4 9834 480 1.66 
5 3539 281 1.14 
6 20823 458 1.64 
7 5559 505 1.94 
8a 
8b 
8243 
9961 
292.3 
348.3 
1.41 
1.67 
9a 
9b 
6893 
9363 
393.8 
535 
1.59 
2.22 
10a 
10b 
4775 
4900 
477.5 
490 
1.98 
1.92 
11a 
11b 
8797 
8652 
472.95 
465.7 
3.36 
3.51 
12a 
12b 
6889 
4892 
551.4 
391.4 
2.11 
1.55 
13a 
13b 
6400 
6417 
345.9 
329.1 
1.75 
1.82 
14a 
14b 
21066 
32871 
322.6 
483.4 
1.00 
2.12 
15 13457 497 2.46 
16a 
16b 
5321 
15733 
273.8 
815.2 
0.93 
2.11 
17a 
17b 
6941 
6572 
341.9 
315.5 
1.83 
1.71 
18 11652 433 2.28 
19 9358 307 1.45 
20a 
20b 
20c 
7766 
11227 
9270 
413.1 
578.7 
501 
1.35 
1.83 
1.47 
21a 
21b 
6701 
6397 
446.7 
412.7 
1.76 
1.62 
22 6144 361 1.11 
23 14538 434 1.62 
24a 
24b 
7636 
5271 
406.2 
289.1 
3.25 
2.26 
25 9060 458 1.96 
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Table 3 Absorbed Tumour dose ratios for consecutive therapies (T) 
 
Study 
no. 
T2 / T1 T3 / T2 
AA 
ratio* 
Tumour 
uptake ratio 
Tumour dose 
ratio 
AA 
ratio* 
Tumour 
uptake ratio 
Tumour dose 
ratio 
2 1.5 1.0 1.5 ± 0.9 1.3 0.5 0.6 ± 0.4 
4 1.1 0.8 0.9 ± 0.4 - - - 
9 1.4 0.4 0.6 ± 0.2 - - - 
11 1.0 1.3 1.3 ± 0.2 - - - 
14 1.6 1.3 2.1 ± 0.9 - - - 
18 1.4 0.3 0.4 ± 0.2 - - - 
20 1.4 0.6 0.9 ± 0.3 0.8 0.4 0.4 ± 0.1 
*AA – Administered activity 
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Table 4 INRC Response 
INRC Response Number (%) 
Complete Remission (CR) 2 (8.3) 
Partial Response (PR) 12 (50) 
Stable Disease (SD) 7 (29.2) 
Progressive Disease (PD) 2 (8.3) 
Mixed Response (MR) 1 (4.2) 
 
Table 4
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